Pasar al contenido principal

ENTENDER EL TRASTORNO BIPOLAR: AVANCES MEDIANTE LA COMBINACION DE FENOTIPADO DIGITAL Y APROXIMACIONES A GENOMA COMPLETO

PID2020-114996RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pathogenic Mis-splicing of CPEB4 in Schizophrenia

  • Ollà, Ivana
  • Pardiñas, Antonio F.
  • Parras, Alberto
  • Hernández, Ivó H.
  • Santos-Galindo, María
  • Picó, Sara
  • Callado, Luis F.
  • Elorza, Ainara
  • Rodríguez-López, Claudia
  • Fernández-Miranda, Gonzalo
  • Belloc, Eulàlia
  • Walters, James T. R.
  • O'Donovan, Michael C.
  • Méndez, Raúl
  • Toma, Claudio
  • Meana, J. Javier
  • Owen, Michael J.
  • Lucas, José J.
Background: Schizophrenia (SCZ) is caused by an interplay of polygenic risk and environmental factors, which may alter regulators of gene expression leading to pathogenic misexpression of SCZ risk genes. The CPEB family of RNA-binding proteins (CPEB1–4) regulates translation of target RNAs (approximately 40% of overall genes). We previously identified CPEB4 as a key dysregulated translational regulator in autism spectrum disorder (ASD) because its neuronal-specific microexon (exon 4) is mis-spliced in ASD brains, causing underexpression of numerous ASD risk genes. The genetic factors and pathogenic mechanisms shared between SCZ and ASD led us to hypothesize CPEB4 mis-splicing in SCZ leading to underexpression of multiple SCZ-related genes. Methods: We performed MAGMA-enrichment analysis on Psychiatric Genomics Consortium genome-wide association study data and analyzed RNA sequencing data from the PsychENCODE Consortium. Reverse transcriptase polymerase chain reaction and Western blot were performed on postmortem brain tissue, and the presence/absence of antipsychotics was assessed through toxicological analysis. Finally, mice with mild overexpression of exon 4–lacking CPEB4 (CPEB4Δ4) were generated and analyzed biochemically and behaviorally. Results: First, we found enrichment of SCZ-associated genes for CPEB4-binder transcripts. We also found decreased usage of CPEB4 microexon in SCZ probands, which was correlated with decreased protein levels of CPEB4-target SCZ-associated genes only in antipsychotic-free individuals. Interestingly, differentially expressed genes fit those reported for SCZ, specifically in the SCZ probands with decreased CPEB4-microexon inclusion. Finally, we demonstrated that mice with mild overexpression of CPEB4Δ4 showed decreased protein levels of CPEB4-target SCZ genes and SCZ-linked behaviors. Conclusions: We identified aberrant CPEB4 splicing and downstream misexpression of SCZ risk genes as a novel etiological mechanism in SCZ., his work was supported by grants to JJL from: Networking Research Center on Neurodegenerative Diseases (CIBERNED) - Health Institute Carlos III (ISCIII) (Collaborative Grant No. PI2018/06-1), Spanish Ministry of Economy and Competitiveness (MINECO) (Grant No. SAF2015-65371-R), Spanish Ministry of Science, Innovation and Universities (MICIU) (Grant No. RTI2018-096322-B-I00) and Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033/FEDER,UE Grant No. PID2021-123141OB-I00); by grants to RM from MINECO (PID2020-119533GB-I00) and World Cancer Research Fund International (2020_021); by grants to CT: No. PID2020-114996RB-I00 (MCIU/AEI/FEDER,UE) and RyC2018-024106-I; and by grants to JJM and LFC from Basque Government (Grant Nos. IT-1211-19 and 1512-22). Cardiff University’s work was supported by grants to JTRW, MCO, and MJO from Medical Research Council Centre (Grant No. MR/L010305/1), Program (Grant No. MR/P005748/1), and Project (Grant Nos. MR/L011794/1, MC_PC_17212). AFP was supported by an Academy of Medical Sciences “Springboard” award (SBF005∖1083). IO was hired through European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement (Grant No. 766124). The Center for Molecular Biology Severo Ochoa is a Severo Ochoa Center of Excellence (MICIN, Award CEX2021-001154-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001154-S)., Peer reviewed